ACADIA Pharmaceuticals In... (ACAD)
NASDAQ: ACAD
· Real-Time Price · USD
25.27
0.01 (0.04%)
At close: Sep 08, 2025, 10:19 AM
0.04% (1D)
| Bid | 25.26 |
| Market Cap | 4.26B |
| Revenue (ttm) | 1.02B |
| Net Income (ttm) | 222.16M |
| EPS (ttm) | 1.33 |
| PE Ratio (ttm) | 19 |
| Forward PE | 31.88 |
| Analyst | Buy |
| Ask | 25.29 |
| Volume | 166,647 |
| Avg. Volume (20D) | 2,021,413 |
| Open | 25.12 |
| Previous Close | 25.26 |
| Day's Range | 25.09 - 25.35 |
| 52-Week Range | 13.40 - 26.65 |
| Beta | 0.75 |
About ACAD
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ACAD
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ACAD stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
ACADIA Pharmaceuticals Inc. is scheduled to release its earnings on
Nov 5, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 months ago
+26.48%
ACADIA Pharmaceuticals shares are trading higher a...
Unlock content with
Pro Subscription
4 months ago
+14.31%
ACADIA Pharmaceuticals shares are trading higher after the company reported better-than-expected Q1 financial results.
1 month ago · seekingalpha.com
ACADIA Pharmaceuticals Inc. (ACAD) Q2 2025 Earnings Call TranscriptACADIA Pharmaceuticals Inc. (NASDAQ:ACAD ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Al Kildani - Corporate Participant Catherine E. Owen Adams - CEO & Director E...
1 month ago · fool.com
Acadia (ACAD) Q2 Revenue Rises 9%Acadia (ACAD) Q2 Revenue Rises 9%
